Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Institut de Cancérologie de Lorraine
Changhai Hospital
Tianjin Medical University Cancer Institute and Hospital
University of Nebraska
Eastern Cooperative Oncology Group
Yonsei University
Wake Forest University Health Sciences
University of Zurich
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Institut Paoli-Calmettes
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Technical University of Munich
European Organisation for Research and Treatment of Cancer - EORTC
University of California, San Francisco